Johnson & Johnson Innovation – JLABS (“JLABS”), in collaboration with Seoul Metropolitan Government (“SMG”), Korea Health Industry Development Institute (“KHIDI”), Janssen Korea Ltd., is launching the Seoul Innovation QuickFire Challenge for Healthcare in the New Normal.
They believe a good idea can come from anywhere, and it’s their goal to find new and innovative technologies that provide solutions to patients from around the world. Working together, they can spark the next great idea that could change the trajectory of health. Seoul, Korea has a robust healthcare innovation ecosystem and Johnson & Johnson is aiming to accelerate breakthroughs through this QuickFire Challenge.
Areas of Interest
They encourage applications from innovators working on all aspects of health care within the “New Normal.” This includes:
Specifically, they’re looking for:
- Health technologies including big data, artificial intelligence, and block chain
- E-health platforms that can improve the patient journey, empowering decision making for physicians and leading to better patient outcomes
- Rapid diagnostics for early detection and monitoring of rare diseases – in particular for Pulmonary Hypertension (PH)
- Companion diagnostics for oncology
- Smart systems for vaccine distribution and patient adherence
They are interested in applications seeking to impact:
- Patient care & shared decision making
- Healthcare related problem solving, including impact that aims to lower cost and improves access to car
- Customized approach for better outcomes
Up to KRW 150,000,000 (~ US $125,000)
- One-year residency at the Seoul Bio Hub
- A year of mentorship and coaching from experts in science and commercialization at the Johnson & Johnson Family of Companies
- Access to programming & resources from the Johnson & Johnson Innovation – JLABS ecosystem
- This is a global challenge. However, if selected as an awardee or finalist, at least one core team member of the applicant company must reside in the Seoul Bio Hub for no less than one year.
- Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.
Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Plans for utilizing the Seoul Bio Hub
- Idea submission outlines interest in the innovation ecosystem in Seoul
For more information, visit https://bit.ly/31LPFhc